490 related articles for article (PubMed ID: 25327352)
1. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
3. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
4. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
5. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
[TBL] [Abstract][Full Text] [Related]
6. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
7. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
8. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients.
Fontaine MJ; Kuo J; Chen G; Galel SA; Miller E; Sequeira F; Viele M; Goodnough LT; Tyan DB
Transfusion; 2011 Dec; 51(12):2611-8. PubMed ID: 21615749
[TBL] [Abstract][Full Text] [Related]
9. False-negative solid-phase platelet crossmatch results due to prozone phenomenon.
Horton RK; Zuccarelli MD; Wakefield LL; DiGuardo MA; Gandhi MJ; Juskewitch JE
Transfusion; 2020 Dec; 60(12):3055-3059. PubMed ID: 33047855
[TBL] [Abstract][Full Text] [Related]
10. Minor impact of patient alloantibodies against human platelet antigen (HPA)-15 in the effectiveness of platelet transfusion: A pilot study.
Inoue H; Sakamoto R; Nishimiya H; Sakamoto H; Terasu S; Aminaka R; Koh Y; Takihara Y; Hirayama F; Kuroishi A
Transfusion; 2021 Mar; 61(3):738-743. PubMed ID: 33166416
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
[TBL] [Abstract][Full Text] [Related]
12. A comparison of volume-reduced versus standard HLA/HPA-matched apheresis platelets in alloimmunized adult patients.
Honohan A; Tomson B; van der Bom J; de Vries R; Brand A
Transfusion; 2012 Apr; 52(4):742-51. PubMed ID: 21981629
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
14. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
[TBL] [Abstract][Full Text] [Related]
15. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
16. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
Lo SC; Chang JS; Lin SW; Lin DT
Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
[TBL] [Abstract][Full Text] [Related]
17. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support.
Moazami N; Itescu S; Williams MR; Argenziano M; Weinberg A; Oz MC
J Heart Lung Transplant; 1998 Sep; 17(9):876-80. PubMed ID: 9773859
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
Abraham AS; Chacko MP; Fouzia NA; Srivastava A; Daniel D
Transfus Med; 2018 Oct; 28(5):392-397. PubMed ID: 29460307
[TBL] [Abstract][Full Text] [Related]
19. Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation.
Lucas G; Culliford S; Green F; Sidra G; Calvert A; Green A; Harrison P; Harvey J; Allen D; Smillie D; Masurekar A; Marks D; Russell N; Massey E
Transfusion; 2010 Feb; 50(2):334-9. PubMed ID: 19874563
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
